definiens: means a combination of ( x ) theActive Agent in a Net Sales Product and ( y ) an active pharmaceutical ingredient, Antibody, recombinant protein, gene therapy or nucleic acidsequence that is not an Active Agent ( where such active pharmaceutical ingredient, Antibody, recombinant protein, gene therapy or nucleicacid sequence is combined with the Active Agent in a single formulation or package, as applicable ), the Net Sales from the CombinationProduct, for the purposes of determining Net Sales - based payments, shall be determined by multiplying the Net Sales ( as determined above)of the Combination Product in a country, during the applicable Net Sales reporting period, by the fraction, A / A+B, where A is the weightedaverage Net Sales price of the Active Agent when sold separately in finished form in such country, and B is the weighted average net sales(determined in the same manner as above ) price of the other active pharmaceutical ingredient, Antibody, recombinant protein, gene therapy or nucleic acid sequence included in the Combination Product when sold separately in finished form in such country, in eachcase during the applicable Net Sales reporting period or, if sales of both the Active Agent and the other active pharmaceutical ingredient, Antibody, recombinant protein, gene therapy or nucleic acid sequence, as applicable, did not occur in such period in such country, then in themost recent Net Sales reporting period in which sales of both occurred in such country . In the event that such weighted average Net Salesprice can not be determined for the Active Agent or the weighted average net sales price can not be determined for the other activepharmaceutical ingredient, Antibody, recombinant protein, gene therapy or nucleic acid sequence, as applicable, included in suchCombination Product, in each case, in a country, the Parties shall reasonably determine, by mutual agreement, the relative value of eachcomponent of such Combination Product and the appropriate method for accounting for sales of such Combination Product in such country, and if the Parties are unable to agree upon the relative value contributed by such Active Agent and such other active pharmaceuticalingredient, Antibody, recombinant protein, gene therapy or nucleic acid sequence, as applicable, within [ * * ], then such matter shall be resolvedpursuant to Schedule 7